Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXS9VY
|
||||
| Drug Name |
(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(2-morpholin-4-yl-ethoxy)-ethoxy]-quinazolin-4-yl}-amine
|
||||
| Synonyms |
CHEMBL356658
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C23H26ClFN4O4
|
||||
| Canonical SMILES |
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCOCCN4CCOCC4
|
||||
| InChI |
InChI=1S/C23H26ClFN4O4/c1-30-21-13-17-20(26-15-27-23(17)28-19-3-2-16(24)12-18(19)25)14-22(21)33-11-10-32-9-6-29-4-7-31-8-5-29/h2-3,12-15H,4-11H2,1H3,(H,26,27,28)
|
||||
| InChIKey |
SPRJHDMLXZXXRJ-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.